CLINICAL QUESTION
Are probiotics in conjunction with antibiotics safe and effective for reducing the risk of Clostridioides difficile–associated diarrhea?
EVIDENCE-BASED ANSWER
Using probiotics in conjunction with antibiotics is safe and effective for reducing the incidence of C difficile–associated diarrhea.1 (Strength of Recommendation: B, inconsistent or low-quality patient-oriented evidence.)
PRACTICE POINTERS
Antibiotics can significantly affect the gut microbiome, resulting in diarrhea and other symptoms. C difficile infection is a form of antibiotic-associated diarrhea that can result in morbidity and mortality, including inflammation, toxic megacolon, and death. Probiotics are live microbial preparations that may promote gut microbiome restoration, which can theoretically prevent diarrhea. The authors of this Cochrane review sought to determine whether probiotics reduce the incidence of C difficile–associated diarrhea.2
This Cochrane review included 47 studies (N = 15,260), including eight new studies since the previous review in 2017.1,3 All studies were conducted in North America, Europe, and Asia. Age range was 4.5 to 78 years; eight studies included only children. Four studies recruited outpatients, six recruited inpatients and outpatients, and 37 recruited inpatients. All patients received an antibiotic to treat an infection, with an adjunctive probiotic to prevent C difficile–associated diarrhea. Any study that used probiotics for treatment rather than prevention of C difficile–associated diarrhea was excluded.
Not all studies had a published protocol or clinical trial registration. Inconsistencies in reported methods and published results reduced the overall quality of the evidence.1
Primary outcomes were reduction in cases of C difficile–associated diarrhea, C difficile colonization, adverse events, and antibiotic-associated diarrhea (ie, diarrhea occurring regardless of C difficile infection in patients recently treated with antibiotics).1 A secondary outcome, evaluated in seven trials (n = 6,553), was the length of hospitalization for those who required inpatient antibiotic treatment for the index infection.
Treatment duration ranged from 1 to 366 days (average = 7–14 days).1 The most common antibiotics prescribed were penicillins and cephalosporins. There was significant heterogeneity in the probiotic species used. The most common species were Saccharomyces boulardii, Lactobacillus rhamnosus, and Lactobacillus acidophilus plus Lacticaseibacillus casei. Some studies used two species, whereas others used three or more. The daily dosage of probiotics ranged from 100 million colony-forming units to 900 billion colony-forming units. The usual duration of probiotic use mirrored the antibiotic course but extended up to 1 week after antibiotic completion in some studies.
The evidence suggests that probiotics may be effective for preventing C difficile–associated diarrhea. Thirty-eight studies (n = 13,179) reported on the incidence of this condition.1 The absolute risk of C difficile–associated diarrhea decreased from 3.2% to 1.6% (absolute risk reduction = 1.6% [16 fewer cases per 1,000 patients treated]). This corresponds to a number needed to treat of approximately 63 (95% CI, 48–97).
Probiotics did not change the length of hospitalization (seven trials; n = 6,553).1 In subgroup analyses, there was no statistically significant difference in outcomes between adults and children. There was little to no difference in length of hospitalization between the intervention and control groups.
The apparent benefit of probiotics increased as the baseline risk of C difficile–associated diarrhea increased.1 In trials with low rates of C difficile–associated diarrhea at baseline (2% or less), probiotics produced little to no absolute benefit, whereas in moderate- and high-risk settings (eg, inpatient settings, outbreak scenarios with control event rates greater than 5%) probiotics were associated with progressively greater relative and absolute risk reductions. This pattern suggests that baseline risk (a proxy for clinical context and exposure intensity) is an important effect modifier and probiotics are more likely to be beneficial in higher-risk settings.
Read the full article
Get immediate access, anytime, anywhere.
Choose a single article, issue, or full-access subscription.
Earn up to 14 CME credits per issue.
